EH 5_2015

Central Laboratory Introducing the new Altair™ 240 analyzer To find out more about the Altair™240 and our comprehensive range of Stanbio Chemistry reagents, visit us at ekfdiagnostics. com or call our US sales team on +1 830 249 0772 EKF’s Altair™240 is a compact, reliable and fully automated clinical chemistry benchtop analyzer. Supported by a full-range of bar-coded, liquid-stable and ready-to-use Stanbio Chemistry reagents, the Altair™240 also features a user-friendly interface with LIS bi-directional connectivity. Whatever your requirements, the Altair™ 240 provides a comprehensive solution tailored to meet the specific needs of your laboratory. NEW • Up to 400 tests per hour (withdouble arm functionality) • 43 reagents and 49 samples on-board • Reliable Stanbio Chemistry reagents reagents Visit us at Medica. 16-19 Nov Stand #C70 Hall3 Copyright: Shutterstock/Tashatuvango EUROPEAN HOSPITAL  Vol 24 Issue 5/15 6 LABORATORY & INFECTION CONTROL HCV prevalence could decrease by 45% due to revolutionary antiviral treatments Update: Hepatitis C management in SpainLeading Spanish experts presented the latest developments in hepatitis C management in their country during the May meeting of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) in Seville Report: Mélisande Rouger The global hepatitis C epidemic is constantly evolving – its prevalence, incidence, contamination mode and genotype distribution have altered considerably over the last decades. Current estimates suggest that up to 180 million individuals are infect- ed with the hepatitis C virus (HCV) worldwide. In Spain, the incidence and preva- lence have decreased significantly over the past decade and, accord- ing to Dr Miguel Angel Simón from Lozano Blesa University Hospital in Zaragoza, just 1% of the population is now HCV positive. ‘We estimate that about 467,000 people are HCV positive, but only 162,049 of them have actually been diagnosed.’ Liver disease revalence is expected to rise Diagnosis in those patients is cru- cial because HCV can trigger liver cirrhosis in 10 to 40% of cases and, at worst, liver failure and hepatocel- lular cancer (HCC). The prevalence of these diseases is expected to rise in the near future. ‘Compensated cirrhosis is expected to rise by 55% by 2030; decompensated cirrhosis should also rise by 60%, HCC asso- ciated to VHC by 105% and hepatic mortality by 95%,” Simón said. The burden of the disease on the healthcare system is already signifi- cant. Thirty percent of all 1,093 liver transplants in Spain were attrib- uted to VHC alone in 2013. New research shows that the virus trans- mission modes have also changed. Nosocomial transmission could be responsible for 73% of cases diag- nosed in tertiary hospitals, especial- ly when multidose tubes are used, Simón explained. ‘Out of 131 cases of acute hepatitis C between 1989 and 2010, 40% could have had noso- comial origin, according to studies published in 2008 and 2012.’ Sexual transmission is not an efficient transmission mode, but is possible. Fairly uncommon in stable heterosexual couples, HCV preva- lence is high and rising in HIV co- infected homosexual males. Cases of reinfection are also more common in this population. HCV is currently the first cause of death in HIV patients, a 200,000 strong population in Spain. As many as 30 to 40% of HIV patients are HCV+, and complications of HCV can be lethal. Prevalence is also higher among prison inmates, as much as 20-30 times more than in the rest of the population. Finally, intravenous drug use is responsible for about 10% of the infection and 80% of intravenous drugs users are VHC+ in Spain. New drugs start a revolu- tion in treatment Prevalence of HCV, however, is expected to decrease by 45%, thanks notably to revolutionary antiviral treatments. ‘There has been a complete revolution in hepatitis C treatment. New drugs are very effective and well toler- ated. One year ago, we had drugs with an efficacy of 30-60% that were very badly tolerated; most of the patients could not end the treatment. Now it’s completely dif- ferent, and it all happened within the past twelve months,’ said Jesús Rodriguez Baño, President of the SEIMC Scientific Committee. Efficacy of the new antivirals is 85-95% within 12 weeks. The drugs target specific strains (or geno- types) and are designed to generate a strong T-cell immune response against HCV. T cells are found to be important in those patients who can clear the virus naturally. Three big families of antivirals are currently being developed: the ‘…asvirs’, which are NSSA inhibi- tors blocking the replication com- plex formation; the ‘…buvirs’, NS5B polymerase inhibitors; and the ‘… previrs’, NS3/4 protease inhibitors. Their power has changed the perception of their patients by epi- demiologists, according to Dr Javier Crespo from Marques de Valdecilla University Hospital in Santander. ‘There’s been a great change in the perception of patients who tradi- tionally did not respond to treat- ment, for instance patients with renal insufficiency or HIV,’ he explained. ‘Daclatasavir combined with sofosbuvir in HIV co-infected patients has a similar efficiency to mono-infected treatment.’ The next step – screening the population Efficacy has a price. Sovaldi, for instance, costs $1,000 per day, or $84,000 for the typical 12-week course. It will be critical for health- care providers to prioritise patients according to the acuteness of their case in a first stage, Rodriguez Baño stressed. The next step would be to screen the population. ‘First we must treat patients with liver disease and cir- rhosis, then we will treat HCV+ patients who don’t have a seri- ous disease, and finally we should screen patients to look for new populations. This has to be dis- cussed soon.’ Following his role as head of the Digestive Hospital Miguel Servet, in Zaragoza, Miguel Angel Simón became head of the Gastroenterology department at Lozano Blesa University Hospital, Zaragoza. He is also Associate Professor at the Faculty of Medicine, University of Zaragoza, where he had gained his bachelor of medicine and gastroenterology specialist qualifi- cations in 1980 and 1985. In 1990, he also received a medical degree from the University of University of Navarra. Today, Dr Simón’s main interests lie in advanced endoscopy, endoscopic therapy and hepatology – especially viral hepatitis qualified services that patients seek- ing private sector treatment want. This is very pertinent question, because – above infrastructural developments over recent years – the costs spent on operation do not support services development, and do not even make the system sus- tainable. According to these facts, nowadays Hungary ranks behind most European Countries in aspects of quality and sustainability. Despite Hungary’s benefits in cir- cumstances and human resources in healthcare, the country has been losing its market share position for European healthcare business. Hungary has to use up its national – public-financed – assets more inten- sively, and re-join the competition for patients willing and able to pay for healthcare services. The country needs to find the answer to ‘How do we do it?’ instead of ‘How can we reject’ the participation of public sector in the competition? Assuring the rights of patients for Hungarian citizens, the country can realise more revenues from the increasing market share, and – depending on the sum and political intent – the country could spend more on the public financed health- care system, improving the quality and the overall accessibility of the system for everyone. Continued from page 2 A question of ... com or call our US sales team on +18302490772

Pages Overview